復宏漢霖(02696.HK)獲潤新生物小分子抑制劑中國區許可專利
復宏漢霖(02696.HK)公布,有關就靶向人類BRAF蛋白V600E突變小分子抑制劑RX208與潤新生物訂立具約束力條款概要一事,今日(11日)公司與對方訂立藥品技術許可協議。
潤新生物將基於必要或合理有用的相關許可專利及許可專有技術,授予公司一項可再許可的獨家許可,供公司在許可區域內研究、開發、生產及商業化許可產品。同時,公司有權將許可產品用於任何人類適應症及任何治療方法,包括但不限於單藥、組合用藥或雞尾酒療法。許可區域為中國(含港澳台地區)。
公司應向潤新生物支付首付款合計9,750萬元人民幣(下同);監管及商業銷售里程碑付款合計不超過10.775億元;除根據協議條款做出的調整及/或抵扣外,以年度淨銷售額的8%到12%計的特許權使用費。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.